Chances and challenges of retinoid X receptor gamma targeting for regenerative multiple sclerosis treatment

Future Medicinal Chemistry

Volumn 7, Issue 18, 2015, Pages 2411-2413

  Merk, Daniel ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

blood brain barrier; multiple sclerosis; retinoid x receptor; RXR subtype selectivity

Indexed keywords

RETINOID X RECEPTOR GAMMA; MOLECULAR LIBRARY;

B LYMPHOCYTE; DISEASE COURSE; EDITORIAL; HUMAN; IN VITRO STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN TARGETING; RECURRENCE RISK; REGENERATIVE MEDICINE; REMYELINIZATION; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD BRAIN BARRIER; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; MOUSE; PATHOPHYSIOLOGY; PHARMACOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD-BRAIN BARRIER; HUMANS; MICE; MULTIPLE SCLEROSIS; REGENERATIVE MEDICINE; RETINOID X RECEPTOR GAMMA; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84951732339     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.163     Document Type: Editorial

References (18)

1. Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol. 10(11), 1026-1034 (2011).
2. Nicholas R, Giannetti P, Alsanousi A, Friede T, Muraro PA. Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des. Devel. Ther. 5, 255-274 (2011).
3. Safavi M, Nikfar S, Abdollahi M. A systematic review of drugs in late-stage development for the treatment of multiple sclerosis: a focus on oral synthetic drugs. Inflamm. Allergy Drug Targets 13(6), 351-366 (2015).
4. Dawson MI, Xia Z. The retinoid X receptors and their ligands. Biochim. Biophys. Acta 1821(1), 21-56 (2012).
5. Vaz B, de Lera ÁR. Advances in drug design with RXR modulators. Expert Opin. Drug Discov. 7(11), 1003-1016 (2012).
6. Krezel W, Dupé V, Mark M, Dierich A, Kastner P, Chambon P. RXR gamma null mice are apparently normal and compound RXR alpha +/-/RXR beta-/-/RXR gamma-/-mutant mice are viable. Proc. Natl Acad. Sci. USA 93(17), 9010-9014 (1996).
7. Krzyzosiak A, Szyszka-Niagolov M, Wietrzych M, Gobaille S, Muramatsu S, Krezel W. Retinoid x receptor gamma control of affective behaviors involves dopaminergic signaling in mice. Neuron 66(6), 908-920 (2010).
8. Huang JK, Jarjour AA, Nait Oumesmar B et al. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat. Neurosci. 14(1), 45-53 (2011).
9. Pombo PM, Barettino D, Ibarrola N, Vega S, Rodríguez-Peña A. Stimulation of the myelin basic protein gene expression by 9-cis-retinoic acid and thyroid hormone: activation in the context of its native promoter. Brain Res. Mol. Brain Res. 64(1), 92-100 (1999).
10. Xu J, Drew PD. 9-cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes. J. Neuroimmunol. 171(1-2), 135-144 (2006).
11. Xu J, Storer PD, Chavis JA, Racke MK, Drew PD. Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. J. Neurosci. Res. 81(3), 403-411 (2005).
12. Zhang-Gandhi CX, Drew PD. Liver X receptor and retinoid X receptor agonists inhibit inflammatory responses of microglia and astrocytes. J. Neuroimmunol. 183(1-2), 50-59 (2007).
13. Yamada S, Kakuta H. Retinoid X receptor ligands: a patent review (2007-2013). Expert Opin. Ther. Pat. 24(4), 443-452 (2014).
14. Connolly RM, Nguyen NK, Sukumar S. Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin. Cancer Res. 19(7), 1651-1659 (2013).
15. Lehman AMB, Montford JR, Horita H et al. Activation of the retinoid X receptor modulates angiotensin II-induced smooth muscle gene expression and inflammation in vascular smooth muscle cells. Mol. Pharmacol. 86(5), 570-579 (2014).
16. Tousi B. The emerging role of bexarotene in the treatment of Alzheimer's disease: current evidence. Neuropsychiatr. Dis. Treat. 11, 311-315 (2015).
17. Rankovic Z. CNS drug design: balancing physicochemical properties for optimal brain exposure. J. Med. Chem. 58(6), 2584-2608 (2015).
18. Dorwald FZ. Lead Optimization for Medicinal Chemists: Pharmacokinetic Properties of Functional Groups and Organic Compounds. Wiley-VCH, Weinheim, Germany (2013).